Cases of organophosphate poisoning treated with high-dose of atropine in an intensive care unit and the novel treatment approaches

• Published in: Toxicology and industrial health Vol. 30; no. 5; pp. 421 - 425
• Main Authors: Karakus, Ali, Celik, Muhammet Murat, Karcioglu, Murat, Tuzcu, Kasim, Erden, Ersin Sukru, Zeren, Cem
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-06-2014; Sage Publications Ltd
• Subjects: Administration, Intravenous; Adolescent; Adult; Aged; Antidotes - administration & dosage; Antidotes - therapeutic use; Atropine; Atropine - administration & dosage; Atropine - therapeutic use; Cholinergics; Critical Care - methods; Drug dosages; Emergency medical care; Female; Glasgow Coma Scale; Hospitals; Humans; Intensive care; Length of Stay - statistics & numerical data; Male; Medicine; Middle Aged; Organophosphate Poisoning - drug therapy; Organophosphate Poisoning - therapy; Organophosphates; Patients; Poisoning; Respiration, Artificial; Retrospective Studies; Secretions; Therapy; Toxicology; Ventilators; Young Adult; Turkey; British Isles, Scotland, Glasgow; alternative treatments; intensive care; Organophosphate poisoning; atropine
• ISSN: 0748-2337; 1477-0393
• DOI: 10.1177/0748233712462478

Organophosphate poisoning is a life-threatening condition, which is being responsible for the symptoms due to cholinergic effects. Clinical status and blood levels of cholinesterase are used its diagnosis. While atropine and pralidoxime (PAM) appear as essential medications, hemofiltration treatments and lipid solutions have been widely studied in recent years. In this study, the importance of high-dose atropine therapy and early intervention and novel treatment approaches are discussed. Records of a total of 25 patients treated for organophosphate poisoning in the intensive care unit (ICU) between April 2007 and December 2011 were evaluated retrospectively. Of the 25 patients, 14 (56%) were male and 11 (44%) were female with a mean age of 34.8 ± 17.66 years (range: 14–77 years). The patients were most frequently admitted in June (n = 4) and July (n = 4) (16%). Of the 25 patients, 22 patients (88%) were poisoned by oral intake, two (8%) by inhalation, and one (4%) by dermal route. Of them, 20 patients (80%) took organophosphates intentionally for suicidal purposes, while five (20%) cases poisoned due to accidental exposure. The scores of Glasgow Coma Scale of nine patients (36%) were below 8 point upon admission to hospital. The highest dose of atropine given was 100 mg intravenously on admission and 100 mg/h/day during follow-up. The total dose given was 11.6 g/12 days. A total of 11 patients (44%) were on mechanical ventilation for a mean duration of 5.73 ± 4.83 days. The mean duration of ICU stay was 6.52 ± 4.80 days. Of all, 23 patients (92%) were discharged in good clinical condition and one patient (4%) was referred to another hospital. This study suggests that atropine can be administered until secretions disappear and intensive care should be exerted in follow-up of these patients. In addition, in case of necessity for high doses, sufficient amounts of atropine and PAM should be available in hospitals.